These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36267132)

  • 1. Factor XI Activation Inhibitors for Treating Thromboses, Embolism, Hypercoagulability, or Fibrotic Changes.
    Sabnis RW
    ACS Med Chem Lett; 2022 Oct; 13(10):1548-1549. PubMed ID: 36267132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XI Activation Inhibitors for Treating Thrombosis, Embolisms, Hypercoagulability, and Fibrotic Changes.
    Sabnis RW
    ACS Med Chem Lett; 2022 Apr; 13(4):530-531. PubMed ID: 35450375
    [No Abstract]   [Full Text] [Related]  

  • 3. Factor XI Activation Inhibitors for Treating Thrombosis, Embolisms, Hypercoagulability, and Fibrotic Changes.
    Sabnis RW
    ACS Med Chem Lett; 2022 Feb; 13(2):154-155. PubMed ID: 35178166
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI.
    Stroo I; Marquart JA; Bakhtiari K; Plug T; Meijer AB; Meijers JCM
    Thromb Haemost; 2018 Feb; 118(2):340-350. PubMed ID: 29378358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of charged groups in factor XI/XIa activity.
    Morgan K; Schiffman S
    J Biol Chem; 1982 Oct; 257(19):11284-7. PubMed ID: 6981645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a factor IX binding site on the third apple domain of activated factor XI.
    Sun Y; Gailani D
    J Biol Chem; 1996 Nov; 271(46):29023-8. PubMed ID: 8910554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Compounds as TEAD Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Sep; 14(9):1152-1153. PubMed ID: 37736181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contact activation of factor XI.
    Jacobs A; Mannhalter C; Margalit R; Schiffman S
    Br J Haematol; 1981 Sep; 49(1):77-86. PubMed ID: 7272231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa.
    Baglia FA; Walsh PN
    J Biol Chem; 2000 Jul; 275(27):20514-9. PubMed ID: 10781579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.
    Sabnis RW
    ACS Med Chem Lett; 2023 Oct; 14(10):1336-1337. PubMed ID: 37849559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Oct; 14(10):1334-1335. PubMed ID: 37849539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):895-896. PubMed ID: 37465294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 May; 14(5):555-556. PubMed ID: 37197476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease Inhibitors for Treating or Preventing Coronavirus Infection.
    Sabnis RW
    ACS Med Chem Lett; 2023 Nov; 14(11):1489-1490. PubMed ID: 37974953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jun; 14(6):707-708. PubMed ID: 37312857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):775-776. PubMed ID: 38894910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):748-749. PubMed ID: 38894901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Aug; 15(8):1184-1185. PubMed ID: 39140065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1045-1046. PubMed ID: 37583830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new sensitive assay for bovine activated factor XI (factor XIa) using a reconstituted coagulation cascade system.
    Kato H; Nakagaki T; Morita T; Kisiel W; Iwanaga S
    Thromb Res; 1987 Nov; 48(4):461-74. PubMed ID: 3502201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.